Pages that link to "Q45740983"

The following pages link to Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption (Q45740983):

Displaying 43 items.

• Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection (Q24536249) (← links)
• Limited durability of viral control following treated acute HIV infection (Q24804986) (← links)
• HIV reservoirs and immune surveillance evasion cause the failure of structured treatment interruptions: a computational study (Q28482710) (← links)
• Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects (Q33949316) (← links)
• Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward (Q34159342) (← links)
• Structured treatment interruptions to control HIV-1 and limit drug exposure (Q34207580) (← links)
• Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection (Q34255654) (← links)
• Current review and clinical management of patients with primary HIV-1 infection: limits and perspectives (Q34322581) (← links)
• Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection (Q34328792) (← links)
• Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy (Q34348075) (← links)
• Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals (Q34359107) (← links)
• Human immunodeficiency virus (HIV)-specific cellular immune responses in newborns exposed to HIV in utero (Q34461381) (← links)
• Structured treatment interruption in patients infected with HIV: a new approach to therapy (Q34510969) (← links)
• Planned interruptions of anti-HIV treatment (Q34547805) (← links)
• Structured treatment interruptions in HIV/AIDS therapy (Q34552833) (← links)
• Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection (Q34619603) (← links)
• Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques (Q34716901) (← links)
• Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy (Q34755325) (← links)
• STI and beyond: the prospects of boosting anti-HIV immune responses (Q34801866) (← links)
• Immune reconstitution (Q34876070) (← links)
• CD8+ T-cell immunity to HIV infection (Q34876135) (← links)
• Supervised interruptions of antiretroviral therapy (Q35108735) (← links)
• Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? (Q35207318) (← links)
• Structured treatment interruptions in HIV infection: benefit or disappointment? (Q35917152) (← links)
• Recent advances in the treatment of HIV/AIDS. (Q35917365) (← links)
• Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia (Q36814047) (← links)
• High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women (Q37012660) (← links)
• Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resum (Q37304799) (← links)
• HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjects (Q37388340) (← links)
• HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control (Q38610690) (← links)
• Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy (Q38959284) (← links)
• HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects. (Q40238137) (← links)
• Piecewise Growth Mixture Tobit Models: Application to AIDS Studies (Q41514088) (← links)
• Nonlinear observer output-feedback MPC treatment scheduling for HIV (Q42043737) (← links)
• Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects (Q42360738) (← links)
• Short communication: CD8(+) T cell polyfunctionality profiles in progressive and nonprogressive pediatric HIV type 1 infection (Q42535693) (← links)
• Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. (Q44216400) (← links)
• A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune (Q45096769) (← links)
• Immune Reconstitution Strategies in HIV. (Q54006280) (← links)
• HIV-1-Specific CD4+ T Cell Responses in Chronically HIV-1 Infected Blippers on Antiretroviral Therapy in Relation to Viral Replication Following Treatment Interruption (Q57080548) (← links)
• [Anti-retroviral treatment interruptions in HIV-infected adults: causes, clinical, immunological and virological consequences] (Q73547808) (← links)
• Less is more? STI in acute and chronic HIV-1 infection (Q74294065) (← links)
• Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV (Q90468887) (← links)